Results 131 to 140 of about 279,772 (360)

Atypical Wounds in Chronic Graft‐Versus‐Host Disease and Peripheral Arterial Disease Caused by Tyrosine Kinase Inhibitors

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT The term “atypical wounds” primarily refers to lesions with immunological or cancerous etiologies. However, these wounds can also be drug‐induced. We report about a 32‐year‐old man with a 6‐year history of chronic myelogenous leukemia (CML) and chronic graft‐versus‐host disease (cGvHD) following an HLA‐compatible allogeneic stem cell ...
E. K. Stuermer   +3 more
wiley   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson   +12 more
wiley   +1 more source

216 Jewish Hospital of St. Louis [PDF]

open access: yes, 1987
https://digitalcommons.wustl.edu/bjc_216/1187/thumbnail ...

core   +1 more source

A comparison of sequential total and activated white cell count in patients undergoing coronary artery bypass grafting, using cardiopulmonary bypass, with and without a white cell filter

open access: yes, 1999
Introduction Cardiopulmonary bypass (CPB) has been shown to induce a systemic inflammatory response similar to the local reaction seen after tissue damage [1].
D Johnson   +6 more
core   +1 more source

Cardiac interventions in patients with achondroplasia: a systematic review. [PDF]

open access: yes, 2020
Patients with achondroplasia and other causes of dwarfism suffer from increased rates of cardiovascular disease relative to the remainder of the population.
Choi, Jae Hwan   +6 more
core   +1 more source

DOES DUAL-ANTIPLATELET THERAPY DECREASE THE RISK OF STROKE FOLLOWING CORONARY ARTERY BYPASS GRAFTING? [PDF]

open access: bronze, 2017
Julian P. T. Higgins   +5 more
openalex   +1 more source

TET3‐Mediated m5C Modification of CCAT2 Accelerates Cardiac Microvascular Endothelial Cell Damage in Acute Coronary Syndrome

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Acute coronary syndrome (ACS) is a clinical syndrome involving myocardial ischemia. This study aimed to elucidate the mechanism of TET3 in ACS‐induced CMEC damage, thereby identifying a new target for ACS treatment. The expression of TET3 in ACS patients and healthy subjects was analyzed.
Jun‐Cheng Liu   +5 more
wiley   +1 more source

Assessment of Discriminant Validity for Measures of Hope and Hopelessness in Adults With an Acute Cardiac Event

open access: yesResearch in Nursing &Health, EarlyView.
ABSTRACT Hope and hopelessness are sometimes considered to be two ends of a spectrum. Hope is associated with positive health outcomes in healthy and ill populations. Conversely, hopelessness has been associated with increased adverse clinical events and death in patients with ischemic heart disease (IHD).
Holli A. DeVon   +4 more
wiley   +1 more source

Relieving the Strain onn Heart Pain: Psychological problems in patients undergoing coronary artery bypass graft surgery [PDF]

open access: yes, 1998
Coronary artery bypass graft surgery (CABG) and percutaneous transluminal coronary angioplasty (PTCA) have become common interventional methods to treat patients with significant coronary artery disease [1].
Duits, A.A. (Annelien)
core   +1 more source

Myocardial ischaemia due to stenosis of the subclavian artery

open access: yesVideosurgery and Other Miniinvasive Techniques, 2011
The internal thoracic artery is often used for reconstruction of coronary arteries. In a proportion of cases the reasonfor bypass failure (internal thoracic artery – coronary artery) is abnormal blood flow in the subclavian artery resultingfrom its ...
Maciej Lewandowski   +3 more
doaj  

Home - About - Disclaimer - Privacy